Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports

Viral Vector and Plasmid DNA Manufacturing Market Size, Share Global Analysis Report, 2018 – 2027

report img

Viral Vector and Plasmid DNA Manufacturing Market By Product (Viral Vectors and Plasmid), By End-User (Biopharmaceutical Companies and Research Institutes), and By Application (Gene & Cancer Therapies, Formulation Development, Viral Infections, and Immunotherapy): Global Industry Perspective, Comprehensive Analysis, and Forecast 2018 – 2027

Industry Insights

The report covers the forecast and analysis of the viral vector and plasmid DNA manufacturing market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the viral vector and plasmid DNA manufacturing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the viral vector and plasmid DNA manufacturing market on a global level.

Global Viral Vector and Plasmid DNA Manufacturing Market Size

To know more about this report | Request Free Sample Copy

In order to give the users of this report a comprehensive view of the viral vector and plasmid DNA manufacturing market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product & service launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

logoReport Scope

Report Attributes

Details

Market Size in 2018

USD 418 Million

Projected Market Size in 2027

USD 2,237 Million

CAGR Growth Rate

20.5 % CAGR

Base Year

2017

Forecast Years

2018 – 2027

Key Market Players

Kaneka Corporation (Eurogentec), Cobra Biologics, VGXI, Inc., DNA manufacturing market include Lonza, FUJIFILM Diosynth Biotechnologies Inc., Genzyme Corporation, Vigene Biosciences Inc., Brammer Bio, Oxford Gene Technology, SIRION Biotech GmbH, FinVector Vision Therapies, VIROVEK, Novasep, SPARK THERAPEUTICS, INC., ALDEVRON, and General Electric Company (GE Healthcare).

Key Segment

By Product, By Application, By Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

The study provides a decisive view of the viral vector and plasmid DNA manufacturing market by segmenting the market based on the product, end-user, application, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The rise in the allocation of funds by private organizations for carrying out research activities is predicted to steer the market expansion over the forecast timespan. In addition to this, manufacturers are implementing new technologies like cell line culture development, expression systems, and cell culture system for effectively handling activities related to viral-based vector development. All these aspects will upsurge market growth during the forecast period. Nonetheless, the risk of mutagenesis & other obstructions in gene therapy as well as huge costs associated with gene treatment will put brakes on the growth of the market over the forecast period.

Based on the product, the market is divided into viral Vectors and plasmid. In terms of end-user, the market is sectored into Biopharmaceutical Companies and Research Institutes. Application-wise, the industry is classified into Gene & Cancer Therapies, Formulation Development, Viral Infections, and Immunotherapy.

logoSome of the key participants in the viral vector and plasmid DNA manufacturing business are

  • Kaneka Corporation (Eurogentec)
  • Cobra Biologics
  • VGXI Inc.
  • DNA manufacturing market include Lonza
  • FUJIFILM Diosynth Biotechnologies Inc.
  • Genzyme Corporation
  • Vigene Biosciences Inc.
  • Brammer Bio
  • Oxford Gene Technology
  • SIRION Biotech GmbH
  • FinVector Vision Therapies
  • VIROVEK
  • Novasep
  • SPARK THERAPEUTICS INC.
  • ALDEVRON
  • General Electric Company (GE Healthcare)

Industry Major Market Players

  • Kaneka Corporation (Eurogentec)
  • Cobra Biologics
  • VGXI Inc.
  • Lonza
  • FUJIFILM Diosynth Biotechnologies Inc.
  • Genzyme Corporation
  • Vigene Biosciences Inc.
  • Brammer Bio
  • Oxford Gene Technology
  • SIRION Biotech GmbH
  • FinVector Vision Therapies
  • VIROVEK, Novasep
  • SPARK THERAPEUTICS Inc.
  • ALDEVRON
  • General Electric Company (GE Healthcare)

Frequently Asked Questions

Viral vectors are altered viruses that are utilized for inserting genetic material into a cell that can be manipulated for the purpose of healing. These viral vectors prevent the new gene from getting degraded through the delivery of gene castle in the targeted cell. The latter makes use of the new gene to carry out its function. Various kinds of viral vectors include adenoviruses, lentiviruses, and adeno-associated viruses.
Strict enforcement of laws by government authorities mandating Viral Vector and Plasmid DNA Manufacturing Market.
According to the report, the global viral vector and plasmid DNA manufacturing market was valued at approximately USD 418 million in 2018 and is expected to reach a value of around USD 2,237 million by 2027
The CAGR value of Viral Vector and Plasmid DNA Manufacturing market is expected to be around 20.5% during 2018-2027.
North America will contribute lucratively towards the global market value over the estimated timeline. The regional market surge is subject to large-scale presence of giant participants in countries such as the U.S. Apart from this, favorable compensation policies along with high acceptance of new Viral Vector and Plasmid DNA Manufacturing Market will drive regional market trends. With regional governments enforcing strict laws pertaining to drug abuse, the market for Viral Vector and Plasmid DNA Manufacturing Market in North America is set to witness exponential growth over years to come. Legalization of cannabis in countries such as Canada and U.S. through passing of acts in parliament is likely to enlarge scope of Viral Vector and Plasmid DNA Manufacturing Market in North America over coming decade.
The global Viral Vector and Plasmid DNA Manufacturing market is led by players like Kaneka Corporation (Eurogentec), Cobra Biologics, VGXI, Inc., DNA manufacturing market include Lonza, FUJIFILM Diosynth Biotechnologies Inc., Genzyme Corporation, Vigene Biosciences Inc., Brammer Bio, Oxford Gene Technology, SIRION Biotech GmbH, FinVector Vision Therapies, VIROVEK, Novasep, SPARK THERAPEUTICS, INC., ALDEVRON, and General Electric Company (GE Healthcare)., and others.